Skip to content

Welcome to Discover Pharma! Today is : October 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Pharmaceuticals and therapeutics

  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Big Picture Bio launches with £2.2M to design cancer drug combinations

    Big Picture Bio has launched with £2.2 million in funding [...]

    September 18, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    SKY-0515 shows 1.59-point cUHDRS difference in Huntington’s disease study

    Skyhawk Therapeutics’ investigational oral treatment SKY-0515 showed a 1.59-point difference [...]

    September 17, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Research & Development

    Calibre secures CQC registration for nationwide AI health service

    Calibre Health Labs has secured CQC registration, allowing its doctors [...]

    September 17, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    NIH funds expanded access programme for Neurizon’s ALS therapy

    A US National Institutes of Health grant will fund an [...]

    September 16, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Sapience Therapeutics gets FDA clearance for ST316 FAP study

    The FDA has cleared Sapience Therapeutics to begin clinical development [...]

    September 16, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    EURneffy recommended for emergency anaphylaxis treatment in NHS Wales

    ALK’s 2mg nasal adrenaline spray has been recommended for use [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Resolution Therapeutics partners with Blood Centers of America for RTX001 programme

    Resolution Therapeutics has partnered with Blood Centers of America to [...]

    September 16, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Researchers develop human iPS cell model of heart failure

    Researchers have developed a human iPS-cell-derived heart tissue model of [...]

    September 16, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing

    Resolution Therapeutics has treated the final patient in its Phase [...]

    September 16, 2026
  • Advanced Therapies,Biotech & Pharma Business,Pharmaceuticals and therapeutics,Research & Development

    Eleva separates biologics platform from Factor H therapy

    Eleva is separating its moss-based biologics platform from its clinical-stage [...]

    September 15, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Lab-grown human neuromuscular junctions advance MND drug discovery
    Categories: Research & Development, Therapeutic Areas
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top